157) Moreover, RANKL expression was measured in cancer cell lines (BICR3, BICR56) by immunohistochemistry and western blot analysis. |
PMID:23979059 DOI:10.1007/s10266-013-0133-2 |
2015 Odontology |
* Co-expression of CD44+/RANKL+ tumor cells in the carcinogenesis of oral squamous cell carcinoma. |
- Receptor activator of nuclear factor-kappa (RANK)/receptor activator of nuclear factor-kappa B ligand (RANKL) signaling helps putative cancer stem cells (CSC) to maintain their stemness. Expression of CD44 and RANKL was analyzed in oral squamous cell carcinoma specimen (n = 191). Moreover, RANKL expression was measured in cancer cell lines (BICR3, BICR56) by immunohistochemistry and western blot analysis. Scanned images were digitally analyzed using ImageJ and the immunomembrane plug-in. CD44 and RANKL expression on protein level was correlated with clinical characteristics and impact on survival. RANKL was co-labeled with CD44 in immunohistochemical and immunofluorescence double labeling experiments. Although high CD44+/RANKL+ co-expression was significantly associated with clinicopathological factors and worse survival, multivariate analysis did not demonstrate high CD44+/RANKL+ co-expression as independent prognostic factor. Immunohistochemical and immunofluorescence double labeling experiments revealed RANKL expression by CD44+ cancer cells. RANKL specificity was confirmed by western blot analysis. For the first time, this study provides evidence that RANKL expression in OSCC might be associated with disease recurrence and a cell compartment measured by CD44+/RANKL+ co-expression within the mucosal epithelial basal layer cells. |
(1)65 *null* | (14)6 therapy | (27)3 of | (40)2 epigenetics |
(2)48 cells | (15)6 tissues | (28)3 patients, | (41)2 growth |
(3)33 and | (16)5 cells, | (29)3 research | (42)2 initiation |
(4)32 cell | (17)5 progression | (30)3 was | (43)2 prevention |
(5)23 patients | (18)5 registries | (31)2 (GC) | (44)2 registry |
(6)15 in | (19)4 at | (32)2 biology | (45)2 study |
(7)14 is | (20)4 deaths | (33)2 but | (46)2 susceptibility |
(8)12 risk | (21)4 has | (34)2 can | (47)2 than |
(9)12 screening | (22)4 mortality | (35)2 care | (48)2 treated |
(10)12 stem | (23)3 (CRC) | (36)2 development | (49)2 treatment |
(11)9 survivors | (24)3 as | (37)2 diagnostic | (50)2 using |
(12)7 with | (25)3 cases | (38)2 drug | |
(13)6 are | (26)3 metabolism | (39)2 drugs |
add keyword